Search This Blog

Wednesday, July 29, 2020

Ginsburg has nonsurgical procedure, due for hospital release by end of week

Justice Ruth Bader Ginsburg on Wednesday underwent a “minimally invasive” procedure on a bile duct stent and is expected to be released from the hospital by the end of the week, according to a Supreme Court spokeswoman.
Ginsburg, 87, had a stent placed last August, and on Wednesday doctors at the Memorial Sloan Kettering Cancer Center in New York City performed a nonsurgical procedure to revise it.
“According to her doctors, stent revisions are common occurrences and the procedure, performed using endoscopy and medical imaging guidance, was done to minimize the risk of future infection,” spokeswoman Kathleen Arberg said. “The Justice is resting comfortably and expects to be released from the hospital by the end of the week.”
This latest development comes just weeks after Ginsburg announced a recurrence of liver cancer. It also marks the third time in three months that she has been hospitalized, including earlier this month to treat an infection after experiencing fever and chills and in May to remove gallstones.
Ginsburg, the leader of the court’s liberal wing, has faced a number of health problems since being appointed to the Supreme Court by former President Clinton in 1993.

She revealed weeks ago that she has been undergoing chemotherapy for liver cancer since May. Ginsburg said the treatment has been “yielding positive results” and that she is able to perform her court duties with “full steam.”
“My most recent scan on July 7 indicated significant reduction of the liver lesions and no new disease,” she said in a July 17 statement. “I am tolerating chemotherapy well and am encouraged by the success of my current treatment. I will continue bi-weekly chemotherapy to keep my cancer at bay, and am able to maintain an active daily routine.”
 
It is the fifth time Ginsburg has been treated for cancer. She had declared in January that she was cancer-free months after completing treatment for a malignant tumor on her pancreas the previous summer.

School Closures Slashed COVID Load, But …

Statewide school closures were associated with a decline in COVID-19 cases and mortality from the disease, along with other non-pharmaceutical interventions, a population-based study found.
From March to May, school closure was associated with a 62% decrease in incidence of COVID-19 (adjusted relative change per week -62%, 95% CI -71% to -49%), and a 58% drop in COVID-19 mortality (adjusted relative change per week -58%, 95% CI -68% to -46%), reported Katherine Auger, MD, of Cincinnati Children’s Hospital Medical Center in Ohio, and colleagues.
Moreover, these associations were largest in states with the lowest incidence of COVID-19 at the time of school closure compared with those with the highest cumulative incidence (-72% relative change in incidence vs -49% change in incidence, respectively), they wrote in JAMA.
However, the authors noted an important caveat to their study: that a variety of non-pharmaceutical interventions, such as mask wearing and closing other non-essential businesses, took place virtually simultaneously, making it difficult to isolate the effects of any single intervention.
The debate over the scope of reopening schools this fall continues to rage, as medicine and politics overlap. Auger and colleagues noted prior research found an association between school closure and reduced transmission of viral respiratory illness, but added that states closed schools without evidence that school closings were effective in curbing the spread of SARS-CoV-2.
“Knowing whether school closure is effective in reducing infections is critical to reduce the negative effects of continued school closure on child health if school closure is ineffective,” they wrote.
The authors performed an interrupted time series analysis of all 50 states from March 9 to May 7, allowing 6 weeks of data collection after school closures in each state. They included other non-pharmaceutical interventions as covariates, including closing non-essential businesses, such as restaurants and bars, and prohibiting large gatherings, based on the effective policy date, and a lag period that allowed these policy changes to occur. States were divided into quartiles based on COVID-19 cumulative incidence per 100,000 population at the time of school closures, all of which were closed beginning on March 13 to March 23.
School closures were associated with an estimated absolute difference of 423.9 cases per 100,000, and an estimated difference in mortality of 12.6 deaths per 100,000. When extrapolated to the U.S. population using mathematical modeling, the authors found school closures were estimated to be associated with 1.37 million fewer cases over a 26-day period, and 40,600 fewer deaths over a 16-day period.
Noting the “close proximity” of other non-pharmaceutical interventions other than school closures, an accompanying editorial by Julie Donohue, PhD, and Elizabeth Miller, MD, PhD, both of the University of Pittsburgh, said it is “difficult to disentangle the potential effect of each intervention.”
Donohue and Miller also said the analysis does not explain how school closures affected viral transmission, writing, “Whether the estimated associations between school closures and COVID-19 outcomes derive from reducing contacts among children or among their parents and caregivers, who are also less mobile as a result, is not known.”
They added there is also no way to know the “optimal duration, combination and sequence of non-pharmaceutical interventions, including school closures,” which would have been easier to figure out if school closures happened after the other interventions were put in place.
The editorialists recommended a “precision public health approach” to any school reopenings this fall, including access to real-time data to “evaluate the effectiveness of specific approaches and adjust accordingly.” They even suggested a specific role for clinicians.
“Health practitioners involved in caring for children should consider formal partnerships with their local schools to help guide reopening and offer micro-level adjustments based on available information,” they wrote.

Disclosures
Auger disclosed support from Agency for Healthcare Research and Quality awards.
Other co-authors also were supported by Agency for Healthcare Research and Quality awards and an award from the National Center for Advancing Translational Sciences, NIH.
Donohue and Miller disclosed no conflicts of interest.

Did Sweden Flatten Its Curve Without a Lockdown?

Despite never implementing a full-scale lockdown, Sweden has managed to flatten its curve, prompting its health leadership to claim victory — but others question the cost of the strategy, as the country has a far higher death toll than its Scandinavian neighbors.
In late July, Sweden’s 7-day moving average of new cases was about 200, down from a peak of around 1,140 in mid-June. Its daily death totals have been in the single digits for two weeks, well below its mid-April peak of 115 deaths in a single day.
However, on a per-capita basis, Sweden far outpaces its Scandinavian neighbors in COVID deaths, with 567 deaths per million people compared with Denmark’s 106 deaths per million, Finland’s 59 deaths per million, and Norway’s 47 deaths per million. The Swedish figure is closer to Italy’s 581 deaths per million.
While the positive trends have led Anders Tegnell, PhD, chief epidemiologist at the Swedish Public Health Agency and architect of Sweden’s coronavirus strategy, to state that the “Swedish strategy is working,” others have criticized the approach, including two dozen Swedish academics who published a recent USA Today editorial.
“In Sweden, the strategy has led to death, grief, and suffering,” they wrote. “On top of that, there are no indications that the Swedish economy has fared better than in many other countries. At the moment, we have set an example for the rest of the world on how not to deal with a deadly infectious disease.”
The Swedish Public Health Agency has not openly stated that herd immunity was its goal, though many suspect this was the intention. Tegnell told reporters last week he thought the recent trends indicated that immunity was now widespread in the country. But with rates of antibody positivity around 10%, that seems impossible. (Officials at the agency did not respond to MedPage Today‘s request for comment.)
So how has Sweden managed to get its outbreak under control?
Behavior Change
While Sweden didn’t officially lock down, many in the country have described a locked-down “feeling” that has eased in the summer months.
At the start of the outbreak, only high schools and universities closed; daycare and elementary schools have been open. Businesses have also remained open, but typically at reduced hours, and restaurants have functioned at reduced capacity.
Swedes have been asked to keep their distance in public, refrain from non-essential travel, and work from home when possible. Gatherings of more than 50 people are also banned. People age 70 and over are advised to stay away from others as much as possible.
Masks were never required and aren’t commonly worn.
This response hasn’t changed over time, through the June surge and into today’s decline, so there’s no definitive explanation for the flattening, though, and experts have several theories.
“Swedes in general have changed their behavior to a great extent during the pandemic and the practice of social distancing as well as physical distancing in public places and at work has been widespread,” said Maria Furberg, MD, PhD, an infectious diseases expert at Umea University Hospital in northeastern Sweden.
“During the months of March to early June, all shops were practically empty, people stopped dining with friends, and families stopped seeing even their closest relatives,” Furberg told MedPage Today. “A lock-down could not have been more effective. Handwashing, excessive use of hand sanitizers, and staying home at the first sign of a cold became the new normal very quickly.”
Mozhu Ding, PhD, an epidemiologist at the famed Karolinska Institute, said the decline is “likely to be a combination of measures taken by individuals, businesses and a widespread information campaign launched by the government.”
“Even without a strict lockdown order, many businesses allowed employees to work from home, and universities are offering distance courses to the students,” Ding told MedPage Today. “Individuals are also taking personal hygiene more seriously, as items like hand sanitizers and single-use gloves are often sold out in pharmacies and grocery stores.”
Immunity
Experts told MedPage Today there weren’t clear data to prove Tegnell’s assertion of widespread immunity in Sweden.
Furberg said there is likely “some sort of unspecific immunity that protects parts of the population from contracting COVID-19” but it’s not necessarily secondary to SARS-CoV-2 exposure.
For instance, a study by the Karolinska Institute and Karolinska University Hospital recently found that about 30% of people with mild or asymptomatic COVID showed T-cell-mediated immunity to the virus, even though they tested negative for antibodies.
“This figure is [more than] twice as high as the previous antibody tests, meaning that the public immunity to COVID-19 is probably much higher than what antibody studies have suggested,” Ding told MedPage Today. “This is of course very good news from a public health perspective, as it shows that people with negative antibody test results could still be immune to the virus at a cellular level.”
Indeed, T-cell immunity is coming into focus as a potentially important factor in COVID infection. A paper published in Nature in mid-July found that among 37 healthy people who had no history of either the first or current SARS virus, more than half had T cells that recognized one or more of the SARS-CoV-2 proteins.
Another 36 people who had mild-to-severe COVID-19 were all found to have T-cell responses to several SARS-CoV-2 proteins, and another 23 people who had SARS-CoV-1 (the virus responsible for the SARS outbreak in 2003) all had lasting memory T cells — even 17 years later — that also recognized parts of SARS-CoV-2.
It could be that T cell immunity is the result of a previous infection with common cold coronaviruses, but this hasn’t yet been established; nor is it certain that T cell immunity is driving Sweden’s decline in COVID cases.
Path Forward
Summertime is another factor that may account for the decline, which began around late June — not directly because of the weather, but social factors related to it.
Swedes are “outdoors more, and students are not at school,” said Anne Spurkland, MD, a professor of immunology at the University of Oslo in Norway.
Also, “perhaps Sweden has finally gotten better control over the disastrous spread of the virus in nursing homes which to some extent can explain their relatively high death rates,” Spurkland told MedPage Today. About half of Sweden’s 5,730 deaths occurred among those in elder care homes.
Norway is still requiring that Swedes quarantine for 10 days when coming into Norway, and Denmark has not fully reopened its borders to its neighbor yet either.
That doesn’t bode well for the Swedish economy. If the goal of avoiding a lockdown was to spare economic woe, its success has been limited.
According to Business Insider, “international tourism and trade are decimated. … Sweden’s National Institute of Economic Research predicts Sweden’s GDP will fall 5.4% in 2020, after predicting a 1% rise [in] December 2019. It also expects unemployment to rise around three percentage points, to 9.6%, between the end of 2019 and the end of 2021.”
Spurkland said it’s still “too early yet to conclude whether the Swedish approach was the wisest over all,” as it remains to be seen whether Norway and other countries that did lock down will avoid a second wave of infections in the fall.
Yet she cautions that choosing to take on a higher case load may have health consequences far beyond the immediate infection.
“What we have learned these months is that COVID-19 is not only about death, it is also about ill health,” Spurkland said. “Quite a number of people going through the infection have long-term symptoms, that may be stopping them from resuming their daily life. We do not know yet how large a proportion of those who get the virus will fall into this category, but it is certainly a concern.”
“So when deciding on taking a herd immunity approach to handle a totally new virus we do not know anything about,” she said, “the Swedish government has also unknowingly put the general population at risk for much long-term ill-health caused by the virus.”
Furberg doesn’t see it that way: “I am very proud of the way Swedes have adapted to the restrictions and regulations and I believe the Public Health Agency of Sweden has picked a good-enough strategy for our country.”

WeGo Health new platform to connect pharma with social media influencers

Brand influencers are common across social media. Assorted Kardashian family members, YouTube house partiers and makeup-wielding Instagrammers talk about the brands and products they use in everyday life—tagged with a #sponsored or #ad hashtag.
However, that’s more difficult in the pharma-to-patient world, in which patient influencers have smaller audiences along with healthcare regulatory rules to follow.
WeGo Health wants to change that with a new service to connect the right patient influencers with pharma companies’ needs. The influencer marketing platform will co-create social media content such as posts, images and videos, which the patient influencer will then post as sponsored content on their personal social channels. While WeGo Health has worked with patients and pharma on similar efforts for 10 years, the resulting content was always posted on its own social channels.

WeGo came up with the platform in part because pharma companies need it, said Richelle Horn, WeGo Health’s senior director of marketing.
In an April survey of 150 of its patient leaders about the effects of the COVID-19 pandemic, patients told WeGo Health that their communities were their No. 1 source of information, while pharma companies ranked dead last at No. 7, garnering only 3% of votes. Overall, patient leaders gave pharma companies a very average “C” grade for patient centricity and overall response to the COVID-19 crisis.
“Influencer marketing for pharmaceuticals and serious diseases is completely different (than consumer influencer marketing)—patient influencers are not for sale at any price, and it’s been a long process for pharma to build trust one influencer at a time,” Horn said.

WeGo will help bridge that trust gap, but it will also use its pharma marketing experience to make sure any content meets legal and regulatory healthcare guidelines. Its goal is to scale up the many nano- and micro-influencers found across health conditions and translate them into a larger overall engagement for pharma.
“What we like about it is that our campaigns can continue beyond a ‘one and done’ typical experience patients told us they often have,” Horn said. “We facilitate the connections, but also grow partnerships between patient and pharma, which is really our mission at its core.”